Background: Current guidelines of empirical antibiotic treatment for inpatients with community-acquired pneumonia recommend antibiotics whose spectrum covers intracellular (atypical) pathogens. No sufficient evidence exists to support the necessity of such coverage, whereas limiting it may reduce toxic effects, resistance, and expense. Our goal was to assess the efficacy of empirical coverage of atypical pathogens in terms of mortality and clinical and bacteriological success.
M

A J O R G U I D E L I N E S
for the treatment of community-acquired pneumonia (CAP) generally differentiate between outpatients, inpatients, and patients hospitalized in intensive care units. [1] [2] [3] [4] Suggested antibiotic regimens for inpatients include a ␤-lactam combined with macrolides, or monotherapy with a respiratory fluoroquinolone. Although Streptococcus pneumoniae remains the leading pathogen in CAP, the rationale for a macrolide supplement or fluoroquinolone monotherapy lies in its ability to cover intracellular (atypical) pathogens such as Chlamydia pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila.
Coverage of the latter pathogen is recommended explicitly for patients in intensive care units. To our knowledge, no randomized, controlled trial has compared, as an objective, the superiority of antibiotic regimens containing coverage of atypical pathogens with regimens lacking such coverage. A systematic review of nonrandomized studies found a significant reduction in mortality when the antibiotic spectrum covered atypical pathogens in 6 of its 8 selected studies. 5 However, all studies were cohort studies, and 2 were restricted to bacteremic pneumococcal pneumonia. 6, 7 In the largest study, 8 the choice of such regimens was associated with an initial lower severity score, thus underlining the potential bias of nonrandomized studies. Whereas the advantage of combination therapy is unproved, dual therapy may increase toxic effects, resistance, and cost. Moreover, an antagonism between penicillin and erythromycin has been shown in vitro and in vivo against S pneumoniae isolates, 9 the most prevalent pathogen causing CAP. 10, 11 The present review evaluates the need for empirical antibiotic coverage of atypical pathogens in adults hospitalized owing to CAP. It includes all randomized, controlled trials that compared an antibiotic regimen containing coverage of atypical pathogens with one not containing such coverage. The main outcome was mortality. Secondary outcomes included clinical efficacy, bacteriological failure, and adverse events.
METHODS
INCLUSION CRITERIA
We included randomized, controlled trials that assessed treatment of CAP in hospitalized adults and in which an antibiotic regimen containing coverage of atypical pathogens was compared with a regimen not containing such coverage. Regimens including a macrolide, fluoroquinolone, tetracycline, doxycycline, or chloramphenicol were considered to afford atypical coverage. Regimens lacking these drugs were considered regimens without atypical coverage. We included oral and intravenous therapies.
Trials that included mainly patients with major immunosuppressive states were not considered for this review. Trials with a dropout rate of more than 30% were excluded.
SEARCH STRATEGY
The search string combined community-acquired infections/ pneumonia, inpatients, and antibiotic names and classes of atypical drugs identified in the previous section (string specified 
OUTCOMES
The primary outcome was overall mortality up to 30 days after the end of treatment. Secondary outcomes included clinical treatment failure, bacteriological eradication, and development of superinfections and adverse events, specifically gastrointestinal events or events resulting in treatment discontinuation.
DATA EXTRACTION
Outcomes were extracted by intention to treat (ITT), including all individuals randomized in the outcome assessment. When data for ITT analysis were unavailable, available cases were assessed. Two reviewers (D.S. and E.R.) independently extracted data from included trials. Methodological assessment was performed using a component approach, including allocation generation and concealment, blinding, and analysis by ITT. Allocation generation and concealment were classified as adequate, unclear, or inadequate, using criteria from the Cochrane Reviewers' Handbook 4.2.2. 12 We did not assess a composite quality scale, because different scales may lead to discordant results. 13 Sensitivity analyses were performed to assess the robustness of the findings per the following trial methods: allocation concealment, allocation generation, and blinding.
DATA ANALYSIS
Relative risks (RRs) with 95% confidence intervals (CIs) are reported. We used a fixed-effects model and compared it with a random-effects model when significant heterogeneity between trials was observed. Heterogeneity of trial results was assessed by calculating a 2 test of heterogeneity and the I 2 measure of inconsistency. Significant heterogeneity was predefined as a 2 test P value smaller than .1 or an I 2 measure larger than 50%. We had anticipated between-trial variation in the estimation of morbidity and mortality for different geographic areas, age groups, sample size, and the drug affording atypical coverage (macrolides or fluoroquinolones). Subgroup analyses to assess the impact of these factors on the main results were performed. A funnel plot estimating the trial precision (logarithm of the RR for efficacy against sample size) was examined to estimate potential asymmetry.
RESULTS
DESCRIPTION OF STUDIES
Our search resulted in 994 references. Fifty-six publications were retrieved for full-text inspection, of which 26 fulfilled the inclusion criteria. Two were withdrawn from analysis owing to unavailable data, 44, 45 and thus 24 trials are included in the review (Figure 1 and Included studies were performed between 1982 and 2004 and encompassed 5015 patients. Inclusion criteria in all studies consisted of adults hospitalized with CAP. The number of participants was 100 or fewer in 8 trials and more than 100 in 16 trials (range, 40-808 participants). All trials were restricted to adults, with a mean age less than 65 years in 12 studies and 65 years or greater in 9. Among the latter, 2 studies were performed in nursing homes, 54, 62 and 1 exclusively included patients older than 70 years. 65 Three studies did not report mean age. Ten studies provided the percentage of patients with chronic obstructive pulmonary disease, ranging from 25% to 52.5%. 64 None analyzed separately results for patients with chronic obstructive pulmonary disease and/or smokers.
Pneumonia was defined by a combination of clinical signs, radiological confirmation (the sole criteria in 2 stud- ies), laboratory values, and/or bacteriological evidence. Thirteen trials further included outpatients, patients with nosocomial pneumonia, and/or patients with bronchitis. In all cases, most of the patients had CAP or could undergo separate analysis. The antibiotic regimens, dosages, and routes of administration are detailed in Table 1 . In nearly all studies, the comparison was between monotherapy in the arm covering atypical pathogens and a ␤-lactam. We found no comparison of a ␤-lactam-macrolide combination with ␤-lactam monotherapy. Treatment duration was conveyed in 14 studies and was almost uniformly 10 days, with no difference between the arms. The main outcome in all studies was clinical treatment failure. Six studies mandated radiological resolution for success definition, and 1 required bacteriological eradication. None chose mortality as the primary outcome.
Eighteen trials assessed bacteriological failure (per patient or per pathogen). Only 8 performed serologic tests for atypical pathogens, of which 1 study found negative results for all tests, 68 and 4 others did not fully report eradication rates. Superinfection and colonization rates were reported in only 5 studies each, precluding further evaluation.
Adverse events were addressed in all studies, although 2 did not specify the number of events per treatment arm.
METHODOLOGICAL QUALITY OF INCLUDED STUDIES
Of the 24 included studies, adequate allocation concealment was reported in 6 and adequate allocation generation in 9. No information was available for the remaining studies. All studies of adequate allocation concealment were also of adequate allocation generation. Seven studies reported results by ITT. Another 13 reported the number of dropouts per study arm, permitting reanalysis by ITT by assuming failure for all dropouts. Four studies did not refer to dropouts and were analyzed only by patients undergoing evaluation.
Follow-up duration was specified in 21 studies, of which 16 defined a specific time for outcome measurement. Follow-up ranged from the end of treatment to 3 months after. Overall mortality was assessed at the end of treatment or at follow-up in all studies. Data at the furthest point in time, up to 30 days, was chosen for analysis. At least 18 of the 24 studies were sponsored by pharmaceutical companies, all of which manufactured the drug with atypical coverage.
OVERALL MORTALITY
Twenty-three of the 24 studies could be evaluated for mortality, encompassing 4846 of 5015 randomized patients (96.6%) (Figure 2) . Six studies reported no deaths, whereas 10 reported mortality rates of 0.4% to 5%; 6, 5% to 8%, and 1, 25%. 51 There was no significant difference between the arms in the overall mortality rate (RR, 1. 
when analyzing studies per allocation generation, allocation concealment, blinding, and the ITT analysis ( Table 2 ). In the funnel plot for overall mortality, results are symmetrically centered around the combined RR.
CLINICAL FAILURE
Clinical failure was the primary outcome in all studies, encompassing 4682 patients. No significant difference between study arms was observed (RR, 0.92 [95% CI, 0.82-1.03]) (Figure 3) Figure 2 . The number of patients who died within the follow-up period (overall mortality). The left side depicts arms with atypical coverage; the right side, arms without atypical coverage. A value of less than 1 favors atypical coverage. Studies are subdivided by the antibiotic used as the atypical regimen, including quinolone therapy (01), macrolide therapy (02), and combined macrolide and quinolone therapy (03). The total indicates the total number of patients (sum of groups 01-03). CAP indicates community-acquired pneumonia; CI, confidence interval; I 2 , measure of inconsistency (see "Methods" section); n/N, number of patients/total number of patients in the study; RR, relative risk; and solid oblong diamond, total events.
[ (Table 2) .
ADVERSE EVENTS
Adverse events per treatment arm were reported for 4261 patients. Total adverse events (RR, 1.02 [95% CI, 0.91-1.13]) and events requiring treatment discontinuation (RR, 0.98 [95% CI, 0.67-1.42]) were similar in both treatment arms, with no heterogeneity seen. Gastrointestinal events were reported in 15 studies and were significantly more common in the arm without atypical coverage (which consisted mainly of ␤-lactams) (RR, 0.73 [95% CI, 0.54-0.99]). However, the definitions of gastrointestinal events differed, some including abdominal pain and some diarrhea alone, thereby precluding an accurate comparison of antibiotic-associated diarrhea.
COMMENT
The objective of our review was to assess empirical antibiotic coverage of atypical pathogens in hospitalized patients with CAP, in terms of mortality and successful treatment. We found no difference in mortality between regimens with coverage of atypical pathogens and regimens without such coverage, persisting in all subgroup analyses. There was a nonsignificant trend toward clinical success to coverage of atypical pathogens, accentuated with quinolone monotherapy. The advantage disappeared when we evaluated high-quality methodological studies alone. A significant advantage in bacteriological eradication was detected in the coverage of atypical pathogens, especially in reference to Legionella species. This advantage was not demonstrated in an analysis restricted to studies of adequate allocation generation and concealment. There was no difference in the frequency of total adverse events between the 2 groups, although more gastrointestinal events (but not explicitly diarrhea) were noted in the arm without atypical coverage.
Mortality data were obtained for 96.6% of randomized patients. The overall mortality rate (adjusted mean mortality rate, 3.7%) was lower than that reported in the literature (eg, MedisGroups, 10.6% 70 ; validation cohort inpatient mortality for the Pneumonia Patient Outcome Research Team, 8.0% 71 ). This is surprising because nearly half of the studies target relatively severe pneumonia cases. Thus, patients recruited to randomized trials may not adequately represent all patients hospitalized with CAP.
Although mortality is the most significant outcome in a potentially lethal infection, all studies chose clinical failure as their primary outcome. This end point is subjective and should be studied with care. Our review clearly demonstrates its potential for bias. A trend in favor of clinical success for the arm covering atypical pathogens originated in studies with unclear allocation generation. Similarly, the clear statistical advantage of that arm, found in the overall analysis of bacteriological eradication rates, did not exist in an analysis restricted to studies of adequate allocation generation. Thus, we should be wary about relying solely on subjective outcomes when comparing treatment regimens for pneumonia, especially because pharmaceutical companies sponsored most studies and many studies were nonblinded.
The similar response of the young and old is somewhat surprising, as an advantage to atypical coverage would be expected in younger people with a higher prevalence of atypical pneumonia. Perhaps this prevalence diminishes in the hospitalized population. The clear advantage of the arm with atypical pathogen coverage in the successful treatment of L pneumophila infections is not surprising, although cases of atypical pneumonia (including L pneumophila) often resolved without such coverage. Coinfections with typical pathogens may explain some of these cases.
We had set out to investigate the contribution of coverage of atypical pathogens to empirical treatment of CAP in hospitalized patients. The most suitable study for our purpose would have been one comparing a drug without atypical coverage (eg, ␤-lactam) with a combination of that drug and a drug with atypical coverage (eg, ␤-lactam and a macrolide). None was found, although the need to add a macrolide to ␤-lactam therapy is a common dilemma manifested within the guidelines themselves. Furthermore, many studies included treatment arms that do not adhere to current guidelines. Therefore, our meta-analysis is chiefly based on comparison of various regimens without coverage of atypical pathogens to monotherapy, mainly quinolone monotherapy. Regarding this comparison, we found no advantage to coverage of atypical pathogens in terms of mortality or clinical success. , measure of inconsistency (see "Methods" section); n/N, number of patients/total number of patients in the study; RR, relative risk; and solid oblong diamond, total events.
Our conclusion of no benefit might be due to lack of power when using available randomized trials. Large observational studies showed benefit for atypical coverage. However, correction for the baseline differences between patients given or not given atypical coverage in these studies may be impossible.
Studies designed specifically to evaluate the necessity of atypical coverage are needed. The optimal design would be a randomized controlled trial comparing the same ␤-lactam in both study arms with and without the addition of antibiotics against atypical pathogens. Studies must be of adequate generation concealment and allocation, and patients included should resemble more closely the general population of inpatients with CAP.
